Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 19/20 | 0.58 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | WNT1 | P04628 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1176384 | 1.00 | DYRK1A (0.58) | DYRK1AGSK3BWNT1 | |
| Formic Acid SCHEMBL5563474 | 0.96 | DYRK1A (0.55) | DYRK1AGSK3BWNT1 | |
| SCHEMBL5042846 | 0.91 | DYRK1A (0.56) | DYRK1AGSK3BWNT1 | |
| SCHEMBL1175586 | 0.91 | DYRK1A (0.56) | DYRK1AGSK3BWNT1 | |
| SCHEMBL5042792 | 0.90 | DYRK1A (0.56) | DYRK1AGSK3BWNT1 | |
| SCHEMBL1176610 | 0.90 | DYRK1A (0.56) | DYRK1AGSK3BWNT1 | |
| SCHEMBL5562209 | 0.88 | DYRK1A (0.51) | DYRK1AGSK3BWNT1 | |
| Formic Acid SCHEMBL5557042 | 0.88 | DYRK1A (0.53) | DYRK1AGSK3BWNT1 | |
| Formic Acid SCHEMBL5563457 | 0.86 | DYRK1A (0.52) | DYRK1AGSK3BWNT1 | |
| SCHEMBL5048444 | 0.83 | PRKAG1 (0.58) | DYRK1AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396833-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-08 | — | — | US | claimed |
| EP-1697378-B1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2007-11-21 | — | — | EP | claimed |
| EP-1474416-B1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | CYP1B1, GRIN2B, CYP4B1 | DYRK1A 1743/4885GSK3B 1097/4885WNT1 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.